Oncocyte (NASDAQ:IMDX) Major Shareholder Purchases $352,096.65 in Stock

Oncocyte Corp (NASDAQ:IMDX) major shareholder Broadwood Partners, L.P. acquired 102,057 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The shares were purchased at an average price of $3.45 per share, with a total value of $352,096.65. Following the acquisition, the insider owned 12,033,896 shares of the company’s stock, valued at approximately $41,516,941.20. This trade represents a 0.86% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, April 20th, Broadwood Partners, L.P. acquired 40,690 shares of Oncocyte stock. The shares were purchased at an average price of $3.88 per share, with a total value of $157,877.20.
• On Friday, April 17th, Broadwood Partners, L.P. acquired 40,114 shares of Oncocyte stock. The shares were purchased at an average price of $3.57 per share, with a total value of $143,206.98.
• On Tuesday, February 10th, Broadwood Partners, L.P. acquired 521,739 shares of Oncocyte stock. The shares were purchased at an average price of $5.75 per share, with a total value of $2,999,999.25.

Oncocyte Stock Performance

Shares of NASDAQ IMDX opened at $3.75 on Thursday. The firm has a market capitalization of $120.64 million, a PE ratio of -2.31 and a beta of 1.52. The firm’s 50 day moving average price is $4.45. Oncocyte Corp has a 52-week low of $2.33 and a 52-week high of $8.51.

Oncocyte (NASDAQ:IMDX) last released its quarterly earnings results on Thursday, March 26th. The company reported ($0.27) earnings per share for the quarter. The firm had revenue of $1.14 million for the quarter.

Analyst Ratings Changes

Several research analysts have recently weighed in on IMDX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncocyte in a report on Friday, March 27th. Wall Street Zen cut shares of Oncocyte from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, Lake Street Capital upped their price target on shares of Oncocyte from $8.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Oncocyte currently has an average rating of “Hold” and an average price target of $12.00.

Oncocyte Company Profile

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.